NALBUFIN (Nalbuphine) *. 17 (Tsiklobutilmetil) -4, 5-to-epoksimorfinan-3, 6, 14-triol.

     Synonyms : Nubain, Nubain.

     Available as hydrochloride.

     On nalbufin chemical structure similar to morphine, but characterized molecule nalbufina (see formula butorfanola) is a place of methyl groups (-SNz) in the nitrogen atom metiltsiklobutilnogo radical.

     Pharmacologically nalbufin is agonistom- antogonistom opioid receptors. Analgesic effect is primarily due to agonisticheskim impact on the c-receptors, but the drug-receptor antagonist m, and therefore does not have expressed mounting action. The general nature of nalbufin close to pentazotsinu, but has a strong analgesic effect with less side effects and less ability to develop tolerance and physical dependence.

     In intramuscular introduction nalbufin is as analgeziruyuschey activity morphine and 2, 3 - 5 times more active than pentazocine. Entering into nalbufin 4 to 5 times less active than in giving muscles.

     Peak plasma concentrations observed after 30 min-1 h after intramuscular introduction; The half-3-6 h Metabolised in the liver; Metabolites made with bile in the intestines. A urine out in significant numbers.

     Applied nalbufin with moderate and severe pain severity after operations in the heart attack. The possibility of pain when nalbufina another origin.

     Enter adults intravenously or intramuscularly at a rate of 0.15 - 0.3 mg (0.00015, 0.0003 grams) per 1 kg of body weight. If necessary, repeat injections every 3 to 4 hours The maximum single dose of 0.3 mg / kg, the maximum daily, 2, 4 mg / kg (representing 70 birth weight 20 kg and 160 mg). Children entering 0,1-0,25 per mg / kg. The maximum single dose of 0.25 mg / kg, the maximum daily 2 mg / kg.

     Nalbufin is a relatively new drug; On his application, and its possible side effects continue to be exploited. Apply the product to no more than three days. Regarding expressed strong sedative effect of the drug. Setback effect on respiration similar to the action of morphine. Relatively few are headache, increased sweating, dry mouth, nausea, vomiting. The drug has little impact on the cardiovascular system, gastrointestinal tract motor.

     Prudence requires the appointment nalbufina patients with respiratory oppression, in violation of the functions of the liver and kidneys, with increased vnutricherepnom pressure.

     The drug passes through the placental barrier and the use of childbirth can cause respiratory depression in the newborn. Caution is needed in the application of the drug in pregnant women.

     In a possible intramuscular pain at the injection.

     It should be borne in mind that the finished drug form nalbufina (nubaina) describes as a preservative disulfit sodium, which can cause in patients with bronchial asthma (with sensitivity to sulfitu) attacks suffocation.

     There nalbufina use of the drug can cause severe attack symptoms.

     Product : in ampoules containing 10 and 20 mg in 1 ml of the drug.

     Storage : using the drug store analgetikov.

Materials allowed to copy only with the active hyperlink to the handbook of medicines